ArticleCells2020
Detection of MET Alterations Using Cell Free DNA and Circulating Tumor Cells from Cancer Patients.
Open access · goldAbstract read
In one paragraph
Article in Cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 27 citations in OpenAlex.
- Review
- Liquid biopsies for detection, characterization, and interception of therapy resistance in thoracic malignancies.Frontiers in oncology · 2026Review
- Combined microfluidic enrichment and staining workflow for single-cell analysis of circulating tumor cells in metastatic prostate cancer patients.Scientific reports · 2024Article
- c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive/HER2-negative metastatic breast cancer.Breast cancer research : BCR · 2024Article
- Molecular Profiling of Circulating Tumour Cells and Circulating Tumour DNA: Complementary Insights from a Single Blood Sample Utilising the ParsortixCurrent issues in molecular biology · 2024Review
- Chemotherapy-free treatment targeting fusions and driver mutations inTherapeutic advances in medical oncology · 2024Article
- Chromatographic analysis of ponatinib and its impurities: method development, validation, and identification of new degradation product.Frontiers in chemistry · 2024Article
- Plasma ddPCR for the detection ofTherapeutic advances in medical oncology · 2024Article
- The Development and Role of Capmatinib in the Treatment of MET-Dysregulated Non-Small Cell Lung Cancer-A Narrative Review.Cancers · 2023Review
- The Role of MET in Resistance to EGFR Inhibition in NSCLC: A Review of Mechanisms and Treatment Implications.Cancers · 2023Review
- The Overview of Perspectives of Clinical Application of Liquid Biopsy in Non-Small-Cell Lung Cancer.Life (Basel, Switzerland) · 2022Review
- Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?British journal of cancer · 2022Review
- Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer.International journal of molecular sciences · 2022Review
- Relevance of Circulating Tumor Cells as Predictive Markers for Cancer Incidence and Relapse.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Clinical potential of circulating free DNA and circulating tumour cells in patients with metastatic non-small-cell lung cancer treated with pembrolizumab.Molecular oncology · 2021Article
- The NHanceBiomedicines · 2021Article
- Has programmed cell death ligand-1Translational lung cancer research · 2021Review
- Current Status and Future Perspectives of Liquid Biopsy in Small Cell Lung Cancer.Biomedicines · 2021Review
- Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib.Lung Cancer (Auckland, N.Z.) · 2021Review
- The Role of the Liquid Biopsy in Decision-Making for Patients with Non-Small Cell Lung Cancer.Journal of clinical medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 6 institutions in 2 countries.
Patricia Mondelo-MacíaLiquid Biopsy Analysis Unit, Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), 15706 Santiago de Compostela, Spain.
Carmela Rodríguez-LópezDepartment of Medical Oncology, Complexo Hospitalario Universitario de Santiago de Compostela (SERGAS), 15706 Santiago de Compostela, Spain.
Laura ValiñaDepartment of Laboratory Medicine, Hospital Universitari Son Espases, Palma, 07120 Balearic Islands, Spain.
Santiago AguínDepartment of Medical Oncology, Complexo Hospitalario Universitario de Santiago de Compostela (SERGAS), 15706 Santiago de Compostela, Spain.
Luis León-MateosDepartment of Medical Oncology, Complexo Hospitalario Universitario de Santiago de Compostela (SERGAS), 15706 Santiago de Compostela, Spain.
Jorge García-GonzálezDepartment of Medical Oncology, Complexo Hospitalario Universitario de Santiago de Compostela (SERGAS), 15706 Santiago de Compostela, Spain.ORCID 0000-0001-7672-9867
Alicia AbaloLiquid Biopsy Analysis Unit, Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), 15706 Santiago de Compostela, Spain.
Oscar Rapado-GonzálezLiquid Biopsy Analysis Unit, Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), 15706 Santiago de Compostela, Spain.
Mercedes Suárez-CunqueiroTranslational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), 15706 Santiago de Compostela, Spain.ORCID 0000-0002-7774-0643
Angel Díaz-LagaresCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain.
Teresa CurielTranslational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), 15706 Santiago de Compostela, Spain.
Silvia Calabuig-FariñasCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain.ORCID 0000-0001-7749-174X
Aitor AzkárateGroup of Advanced Therapies and Biomarkers in Clinical Oncology, Institut d'Investigació Sanitària de les Illes Balears (IdISBa), Palma, 07120 Balearic Islands, Spain.
Antònia Obrador-HeviaGroup of Advanced Therapies and Biomarkers in Clinical Oncology, Institut d'Investigació Sanitària de les Illes Balears (IdISBa), Palma, 07120 Balearic Islands, Spain.ORCID 0000-0002-4630-2077
Ihab AbdulkaderDepartment of Pathology, Complexo Hospital Universitario de Santiago de Compostela (SERGAS), Universidade de Santiago de Compostela, 15706 Santiago de Compostela, Spain.
Laura Muinelo-RomayLiquid Biopsy Analysis Unit, Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), 15706 Santiago de Compostela, Spain.ORCID 0000-0002-7456-7531
Roberto Diaz-PeñaLiquid Biopsy Analysis Unit, Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), 15706 Santiago de Compostela, Spain.
Rafael López-LópezLiquid Biopsy Analysis Unit, Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), 15706 Santiago de Compostela, Spain.
Complejo Hospitalario Universitario de Santiago · ESInstituto de Investigación Sanitaria de Santiago · ESHealth Research Institute of the Balearic Islands · ESUniversidade de Santiago de Compostela · ESUniversidad Autónoma de Chile · CLUniversitat de València · ES
Funding
No grant is acknowledged in the PubMed record.
Abstract
MET alterations may provide a potential biomarker to evaluate patients who will benefit from treatment with MET inhibitors. Therefore, the purpose of the present study is to investigate the utility of a liquid biopsy-based strategy to assess MET alterations in cancer patients. We analyzed
Indexed as
Gene DosageAntineoplastic AgentsBiomarkers, TumorCase-Control StudiesCell-Free Nucleic AcidsDrug Resistance, NeoplasmErbB ReceptorsFemaleHumansLiquid BiopsyMaleNeoplasmsNeoplastic Cells, CirculatingProspective StudiesProtein Kinase InhibitorsProto-Oncogene Proteins c-metAntineoplastic AgentsBiomarkers, TumorCell-Free Nucleic AcidsEGFR protein, humanErbB ReceptorsMET protein, humanProtein Kinase InhibitorsProto-Oncogene Proteins c-metcirculating free DNA (cfDNA)circulating tumor cells (CTCs)MET amplificationMET copy numberMET protein expressiontargeted therapy
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.